Company profile
JOHNSON & JOHNSON
NYSE:JNJBiotechnology: Pharmaceutical Preparations
Drug pipeline (198)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| DARZALEX | approved | $4.2BQ2 2026 | 37 | approved |
| TREMFYA | approved | $2.0BQ2 2026 | 54 | approved |
| TREMFYA | approved | $2.0BQ2 2026 | 54 | approved |
| INVEGA | approved | $1.0BQ2 2026 | 13 | approved |
| INVEGA SUSTENNA | approved | $1.0BQ2 2026 | 29 | approved |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (2296)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01157351 | phase4 | completed | 2010-05-01 | 2013-12-01 | Janssen Scientific Affairs, LLC | 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated |
| NCT00752427 | phase3 | completed | 2004-06-01 | — | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliperidone in the Treatment of Geriatric Subjects With Schizophrenia |
| NCT00946985 | phase4 | terminated | 2009-06-01 | 2010-03-01 | Ortho-McNeil Janssen Scientific Affairs, LLC | 28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years |
| NCT01349465 | phase3 | completed | 2011-07-04 | 2016-01-05 | Janssen R&D Ireland | 3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection |
| NCT03039192 | phase3 | completed | 2017-06-09 | 2018-12-18 | Janssen Research & Development, LLC | 54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide |
FDA applications (135)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 220149 | 2026-03-17 | NDA | JANSSEN BIOTECH INC | |||||
Loading… | ||||||||
| NDA 220092 | 2026-02-27 | NDA | JANSSEN PRODUCTS LP | |||||
Loading… | ||||||||
| BLA 761484 | 2026-02-13 | BLA | JANSSEN BIOTECH, INC. | |||||
Loading… | ||||||||
| NDA 219683 | 2025-09-09 | NDA | JANSSEN BIOTECH INC | |||||
Loading… | ||||||||
| BLA 761430 | 2025-04-29 | BLA | JANSSEN BIOTECH, INC. | |||||
Loading… | ||||||||